ESTA Overview

Insider Buying Activity: 17.0% of the weighted holdings in the Fidelity MSCI Health Care Index ETF (FHLC) have seen insider buying in the past six months.

Avantor Inc (AVTR): This company, making up 0.12% of FHLC, has had two directors and officers purchase shares recently, with the ETF holding $3,215,377 worth of AVTR.

Establishment Labs Holdings Inc (ESTA): Representing approximately 0.02% of FHLC, ESTA has also seen insider purchases from two directors and officers, with the ETF holding $490,723 worth of ESTA.

Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

Company Performance: Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported Q3 2025 revenue of $53.78 million, a 33.7% year-over-year increase, exceeding analyst estimates by $1.5 million, while the EPS of negative $0.38 also surpassed expectations.

Growth in US Market: The company's US business, a key growth area, saw a 16% increase despite a seasonally slower quarter for breast procedures, with management anticipating a 20% market share in US breast augmentation by the end of 2025.

Sales Acceleration: Management noted that the fourth quarter is typically the strongest for breast augmentation, and they are already observing sales acceleration in the US market.

Investment Considerations: While ESTA shows potential as an investment, the article suggests that certain AI stocks may offer better upside potential and lower downside risk.